2Q21 earnings presentation

2021 vs. 2Q19 Surgical growth in all categories + + + Alcon ● ● ● ● ● ● Ongoing roll-out of PanOptix and Vivity driving market share Penetration growth of ATIOLS Consumables growth across procedure types (cataract, vit-ret and refractive) despite varied international market recovery Healthy demand for equipment, aided by innovation and strong commercial execution Expansion of new operating room capacity Refractive continues to benefit from higher discretionary income and focus on health and wellness 1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. Net Sales (USD $M) $1,051 $300 $588 $163 2Q19 $1,206 $387 $620 $199 2Q21 Implantables Consumables Equipment/other (USD) (CC)¹ 15% 14% 29% 29% 5% 4% 22% 23% 14

View entire presentation